The Record - for physicians and other health care providers to share with their office staffs

Forward to a friend  |  Subscribe  |  The Record Archive  |  Contacts  |  bcbsm.com  |  Print entire issue

March 2017

All Providers

Bill dates of service correctly to boost accuracy of claims processing

Blue Cross Blue Shield of Michigan frequently receives medical claims with an incorrect date of service. To help ensure that the correct dates are used, we want to let you know that Blue Cross defines “date of service” as the actual date the service was rendered to the patient.

For example, the date of service is the date when a patient receives an X-ray or the date a lab or pathology sample is taken.

Even when the tests are analyzed on a different day, use the date of service as it’s described in this article to bill the charge. Following this direction will help us process your claims with greater accuracy.


Members can get medications synchronized through Express Scripts, starting March 15

Blue Cross Blue Shield of Michigan and Blue Care Network will launch their medication synchronization program with Express Scripts for all commercial (non-Medicare) lines of business, starting March 15, 2017.

This program will allow medications for a patient to be refilled on the same day. Not only does the member get the convenience of fewer trips to the pharmacy, but the program may also increase medication adherence.

We’re adding this program in response to Michigan Public Act 38 of 2016, which requires that insurers allow members to synchronize multiple maintenance drug prescriptions for chronic long-term care conditions. The medication synchronization legislation takes effect March 15, 2017.

Which drug claims apply to the medication synchronization program?
The program allows:

  • Medication synchronization of maintenance drugs for chronic long-term care conditions, with the exception of:
    • Most Schedule 2-5 controlled substances (anti-epileptic prescriptions allowed)
    • Select prescription drugs that are limited to certain fill requirements
  • Medication synchronization on prescriptions that have authorized refills remaining

How will we synchronize prescription drugs?

  • When a participating pharmacy submits a claim for a member that meets the criteria, our claims processer (Express Scripts) will apply a prorated, daily cost-sharing rate to the maintenance prescription drugs. The claims processing system will allow a pharmacist to dispense up to 29 days of acceptable drugs.
  • Participating pharmacies will collect from the member the applicable cost share and receive a dispensing fee for each synchronized prescription claim submitted.

Blue Cross and Blue Care Network no longer cover EpiPen® brand drugs, starting March 1

To provide the best value for our members, Blue Cross Blue Shield of Michigan and Blue Care Network commercial plans no longer cover EpiPen® 0.3 mg and EpiPen Jr® 0.15 mg auto-injector drugs, effective March 1, 2017.

EpiPen injectors are used to treat allergic reactions.

Blue Cross and BCN will provide coverage for the authorized generic epinephrine auto-injectors. These generics are considered brand products and are available to the member at the preferred brand copay amount.

Both the epinephrine auto-injectors and the EpiPen products are manufactured by Mylan and have the same drug formulation and device functionality. Prescriptions written for EpiPen and EpiPen Jr are interchangeable with the ephinephrine auto-injector products when filled at the pharmacy.

Note: These changes don’t apply to MESSA groups.

Here’s a look at the alternatives for excluded drugs and the average cost:

Drugs not covered, beginning March 1, 2017

Covered alternatives

Epipen® (epinephrine injection, 0.3 mg)
2-Pak

$730**

Epinephrine 0.3 mg auto injector 2-Pak

$375**

Epipen Jr® (epinephrine injection, 0.15 mg) 2-Pak

$730**

Epinephrine 0.15 mg auto injector 2- Pak

$375**

**Approximate cost per package, based on the average wholesale price

If you’ve been prescribing EpiPen or EpiPen Jr, discuss the covered alternatives with your patients.


Online prescription drug lists updated

Blue Cross Blue Shield of Michigan updated its 2017 online prescription drug lists, or formularies.

We update these lists to help ensure patient safety and to help prescribers select the most effective and affordable drug therapy for patients.

You can view the most recent prescription drug list updates at bcbsm.com/rxinfo. You can also see other pharmacy-related information at this link.

These drug lists can help prescribers make better-informed decisions. This can lead to increased medication adherence and help providers explain prescription drug coverage to members.


InterQual® Criteria books going digital in 2017

Starting this year, McKesson Health Solutions’ InterQual Criteria books will only be available online. Any new or updated criteria will also be available only online. You won’t receive a printed InterQual book in 2017 or beyond. Instead, every user will have online access within the InterQual View application.

Blue Cross Blue Shield of Michigan will begin using the 2017 criteria in early August 2017.

Coming soon
To prepare for the online criteria release, your organization will receive registration information in April 2017 with detailed instructions. These instructions will include how to set up and use the InterQual View software. You’ll also receive instructions on how to register for online access to McKesson’s Download Central and Customer Hub. If you’re licensed with McKesson directly, you may have already registered.


Submit ‘void’ claim request, not refund request

Provider Inquiry will no longer accept refund requests through the mail. If you mail a refund request, it will be returned to you. We ask that you submit refund requests as a void claim.

For refund request instructions, see the January 2016 Record article.


HCPCS update: Codes added, deleted

The Centers for Medicare & Medicaid Services has added six new codes and deleted three codes as part of its regular quarterly HCPCS updates. The codes are listed below.

Code

Change

Coverage comments

Effective date

A4224

Added

Covered

Jan. 1, 2017

C1842

Added

Not covered

Jan. 1, 2017

G0659

Added

Covered

Jan. 1, 2017

0001U

Added

Not covered

Feb. 1, 2017

0002U

Added

Not covered

Feb. 1, 2017

0003U

Added

Covered

Feb. 1, 2017

The deleted codes are listed below.

Code

Change

Effective date

G0477

Deleted

Dec. 31, 2016

G0478

Deleted

Dec. 31, 2016

G0479

Deleted

Dec. 31, 2016


We’re updating ClaimsXten™ for second quarter of 2017

Blue Cross Blue Shield of Michigan is updating ClaimsXten for the second quarter of 2017.

This helps ensure that we're using the most current CPT® code updates, Centers for Medicare & Medicaid Services guidelines and specialty society guidelines. We also reference information from industry seminars and publications, as well as Blue Cross payment policy revisions, when performing our quarterly ClaimsXten updates.

We reserve the right to make changes or corrections when required or new information becomes available. In some instances, we may apply changes to ClaimsXten retroactively.


BlueCard® connection: How does a BlueCard member’s filing limitations affect adjustment claims I bill to Blue Cross?

In addition to Blue Cross Blue Shield of Michigan’s timely filing policy, some BlueCard members have specific filing limitations as part of their contracted group benefits. Both policies apply to claims you report for BlueCard members. To avoid claim rejections, promptly report all BlueCard original and replacement claims.

For more information on the BlueCard program, including links and articles on online tools, refer to the BlueCard chapter of the online provider manuals.

If you’re experiencing issues with the information provided in the BlueCard chapter of the online manual — or if you’d like more information on a particular topic — contact your provider consultant.

Want to suggest a topic to be covered in this series? Send an email to ProvComm@bcbsm.com and put “BlueCard series” in the subject line.


Coding corner: When is it appropriate to use a ‘history of’ code when reporting cancer?

Coding tip
If a cancer is active and being treated, it shouldn’t be considered “past medical history” until the cancer is no longer active.

As you’ve read in “Coding corner” before, selecting the code that best captures a patient’s condition at the time of his or her visit can be a challenge, but keeping some basic guidelines in mind can help. Here’s what you need to know about coding for cancer.

Your documentation should always specify one of the following:

  • The cancer is active and still being treated.
  • The cancer is no longer active or there’s no recurrence and no further treatment is necessary.

When coding for active malignancy versus coding for a person with a history of malignancy, ICD-10-CM coding guidelines are specific. Section I.C.2.m. states:

“When a primary malignancy has been excised but further treatment, such as an additional surgery for the malignancy, radiation therapy or chemotherapy is directed to that site, the primary malignancy code should be used until treatment is completed.

“When a primary malignancy has been previously excised or eradicated from its site, there is no further treatment (of the malignancy) directed to that site, and there is no evidence of any existing primary malignancy, a code from category Z85, Personal history of malignant neoplasm, should be used to indicate the former site of the malignancy.”

Scenario one:
A patient with a history of breast cancer and mastectomy of the right breast — but who has no evidence of cancer or isn’t currently receiving treatment — comes in for an office visit. The provider documents that there are no presenting problems that may affect the overall plan of care and that the patient isn’t receiving active adjuvant therapy. In this scenario, a personal history code should be used. Example: Z85.3 Personal history of malignant neoplasm of breast

Patients who currently have cancer
In the scenarios below, the cancer is still being actively managed, so a current malignancy code should be used. Example: C50.111 Malignant neoplasm of central portion of right female breast

Scenario two:
A patient diagnosed with breast cancer returns to the office for a visit after a mastectomy and is currently receiving radiation therapy.

Scenario three:
A patient, diagnosed with breast cancer last year, had a mastectomy followed by radiation and chemotherapy. She was hormone receptive positive and is currently taking Arimidex®.

In summary
To ensure best documentation practices, refer to the ICD-10-CM guidelines to assist with the code selection that clearly supports the documentation. Clinical evidence needs to be documented to support an active diagnosis of cancer.

The documentation must clearly state that the cancer is currently and actively being treated and managed. If the cancer has been excised or eradicated and there’s no evidence of recurrence and no further treatment is needed, then it’s appropriate to use a “personal history” code.

None of the information included in this article is intended to be legal advice and, as such, it remains the provider’s responsibility to ensure that all coding and documentation are done in accordance with all applicable state and federal laws and regulations.


Correction: Grede Holdings LLC’s drug plan applies to Brillion retirees (Wisconsin)

An article in the "Group Benefit Changes" section of the January billing chart contained incorrect information about the Grede Holdings LLC’s drug plan. For “drug plan,” it should have specified that it relates to only Brillion retirees (Wisconsin). To see all the information on Grede Holdings, go to the “Group Benefit Changes” section of the March billing chart.


Billing chart: Blues highlight medical, benefit policy changes

You’ll find the latest information about procedure codes and Blue Cross Blue Shield of Michigan billing guidelines in the following chart.

This billing chart is organized numerically by procedure code. Newly approved procedures will appear under the New Payable Procedures heading. Procedures for which we have changed a billing guideline or added a new payable group will appear under Updates to Payable Procedures. Procedures for which we are clarifying our guidelines will appear under Policy Clarifications. New procedures that are not covered will appear under Experimental Procedures.

You will also see that descriptions for the codes are no longer included. This is a result of recent negotiations with the AMA on use of the codes.

We will publish information about new BCBS groups or changes to group benefits under the Group Benefit Changes heading.

For more detailed descriptions of the BCBSM policies for these procedures, please check under the Medical/Payment Policy tab in Explainer on web-DENIS. To access this online information:

  • Log in to web-DENIS.
  • Click on BCBSM Provider Publications & Resources.
  • Click on Benefit Policy for a Code.
  • Click on Topic.
  • Under Topic Criteria, click on the drop-down arrow next to Choose Identifier Type and then click on HCPCS Code.
  • Enter the procedure code.
  • Click on Finish.
  • Click on Search.
Code* BCBSM changes to:
Basic Benefit and Medical Policy, Group
Variations Payment Policy, Guidelines
UPDATES TO PAYABLE PROCEDURES

38204-38215, 38220, 38221, 38230, 38232, 38241, 38242, S2140, S2142, S2150

Basic benefit and medical policy

Bone marrow/hematopoietic stem cell transplants for plasma cell dyscrasias

The safety and efficacy of specified bone marrow/hematopoietic stem cell transplants for plasma cell dyscrasias, including multiple myeloma and POEMS syndrome, have been established. They may be considered useful therapeutic options for patients meeting selection criteria. Inclusionary criteria have been updated, effective March 1, 2017.

Inclusions:
Multiple myeloma
The following hematopoietic stem-cell transplantations for multiple myeloma are considered established:

  • Single or second (salvage) autologous hematopoietic stem-cell transplantation.
  • Tandem autologous-autologous hematopoietic stem-cell transplantation for patients who fail to achieve at least a near-complete or very good partial response after the first transplant in the tandem sequence. (A near complete response, as defined by the European Group for Blood and Marrow Transplant, or EBMT, is the disappearance of M protein at routine electrophoresis, but positive immunofixation. A very good partial response has been defined as a 90 percent decrease in the serum paraprotein level.)
  • Tandem transplantation with an initial round of autologous hematopoietic stem-cell transplantation followed by a non-marrow-ablative conditioning regimen and allogeneic hematopoietic stem-cell transplantation for the treatment of newly diagnosed multiple myeloma patients.
  • Myeloablative or nonmyeloablative allogeneic hematopoietic stem-cell transplant is an acceptable option in patients with responsive or primary progressive disease as salvage therapy when these  patients  have undergone a prior autologous hematopoietic stem-cell transplant.

POEMS syndrome
Autologous hematopoietic stem-cell transplantation to treat disseminated POEMS syndrome.

Exclusions:
Multiple myeloma

  • Allogeneic hematopoietic stem-cell transplantation, myeloablative or nonmyeloablative, as upfront therapy of newly diagnosed multiple myeloma is considered experimental.
  • More than two tandem transplants, two single transplants or a single and a tandem transplant per patient for the same condition.
  • The routine harvesting or storage of an individual’s umbilical cord blood for possible use at some unspecified time in the future.

POEMS syndrome
Allogeneic and tandem hematopoietic stem-cell transplantation to treat POEMS syndrome.

43771, 43772, 43773, 43774, 43886,
43887, 43888

Basic benefit and medical policy

Payable codes

Diagnosis codes K95.01, K95.09, K95.81 and K95.89 are now payable in addition to existing payable diagnosis codes.

69710, 69711, 69714, 69715, 69717, 69718, L8690, L8691, L8692, L8693

Basic benefit and medical policy

Bone-anchored hearing devices

The safety and effectiveness of unilateral or bilateral fully or partially implanted bone-conduction (bone-anchored) hearing aids have been established. They may be considered a useful therapeutic option when indicated. Inclusionary criteria have been updated, effective March 1, 2017.

Inclusions:
Conductive hearing loss
Unilateral or bilateral fully or partially implantable bone-conduction (bone-anchored) hearing aids may be necessary as an alternative to an air-conduction hearing aid in patients aged 5 and older with conductive or mixed hearing loss who also meet at least one of the following criteria:

  • Congenital or surgically induced malformations (e.g., atresia) of the external ear canal or middle ear
  • Chronic external otitis or otitis media
  • Tumors of the external canal or tympanic cavity
  • Chronic dermatitis of the external canal prohibiting the usage of an air conduction hearing aid and meet the following audiologic criteria:
    • A pure-tone average bone-conduction threshold measured at 0.5, 1, 2, and 3 kHz or better than or equal to 45 dB (OBC and BP100 devices), 55 dB (Intenso device) or 65 dB (Cordele II device).

For bilateral implantation, patients should meet the above audiologic criteria and have symmetrically conductive or mixed hearing loss as defined by a difference between left and right side bone-conduction threshold of less than 10 dB on average measured at 0.5, 1, 2 and 3 kHz (4 kHz for OBC and Ponto Pro), or less than 15 dB at individual frequencies.

Sensorineural hearing loss
A unilateral implantable bone-conduction (bone-anchored) hearing aid may be considered medically necessary as an alternative to an air-conduction contralateral routing of signal hearing aid in patients aged 5 and older with single-sided sensorineural deafness and normal hearing in the other ear.

Note: The Audiant® bone conductor is a bone-conduction hearing device. While this product is no longer actively marketed, patients with existing Audiant devices may require replacement, removal or repair.

Exclusions:
Other uses of implantable bone-conduction (bone-anchored) hearing aids, including use in patients with bilateral sensorineural hearing loss, are considered experimental.

69930, 92601, 92602, 92603, 92604, L7510, L8614, L8615, L8616, L8617, L8618, L8619, L8621, L8622, L8623, L8624, L8627, L8628, L8629

Basic benefit and medical policy

Cochlear implant

The safety and effectiveness of U.S. Food and Drug Administration-approved bilateral or unilateral cochlear implants and associated aural rehabilitation and cochlear implantation with a hybrid cochlear implant or hearing aid device that includes the hearing aid integrated into the external sound processor of the cochlear implant (e.g., the Nucleus® Hybrid™ L24 Cochlear Implant System) have been established. The implants may be considered useful therapeutic options when indicated.

Inclusions:
Unilateral or bilateral cochlear implantation is considered an established, safe and effective therapy if all of the following criteria are met:

  • FDA-approved cochlear implant
  • 12 months of age or older**
  • Bilateral severe to profound pre- or postlingual (sensorineural) hearing loss
    • Defined as a hearing threshold of pure-tone average of 70 dB hearing loss or greater at 500, 1000, 2000 Hz
  • Limited benefit from appropriately fitted hearing aids (based on speech perception scores)
  • Evidence of a functioning auditory nerve
  • Freedom from middle ear infection, lesions in the auditory nerve and acoustic areas of the central nervous system
  • Accessible cochlear lumen that is structurally suited for implantation
  • Motivated member or family who has appropriate expectations (if member is a child) with cognitive ability to use auditory clues and a willingness to participate in a rehabilitation program

Cochlear implant with a hybrid device that includes the hearing aid integrated into the external sound processor of the cochlear implant (e.g., the Nucleus® Hybrid L24 Cochlear Implant System) may be considered established for patients ages 18 and older who meet all of the following criteria:

  • Bilateral severe-to-profound high frequency sensorineural hearing loss with residual low-frequency hearing sensitivity
  • Receive limited benefit from appropriately fit bilateral hearing aids
  • Have the following hearing thresholds:
    • Low frequency hearing thresholds no poorer than 60 dB hearing level up to and including 500 Hz (averaged over 125, 250 and 500 Hz) in the ear selected for implantation
    • Severe to profound mid-to-high frequency hearing loss (threshold average of 2000, 3000 and 4000 Hz ≥75 dB hearing level) in the ear to be implanted
    • Moderately severe to profound mid-to-high frequency hearing loss (threshold average of 2000, 3000 and 4000 Hz ≤ 60 dB hearing level) in the contralateral ear
    • Aided consonant-nucleus-consonant word recognition score from 10 percent to 60 percent in the ear to be implanted in the preoperative aided condition and in the contralateral ear will be equal to or better than that of the ear to be implanted but not more than 80 percent correct

** In certain situations, implantation may be considered before 12 months of age. One scenario post meningitis when cochlear ossification may preclude implantation. Another is in cases with a strong family history, because establishing a precise diagnosis is less uncertain.

Exclusions:

  • Cochlear implantation as a treatment for patients with unilateral hearing loss with or without tinnitus
  • Upgrades of an existing, functioning external system to achieve aesthetic improvement, such as smaller profile components or a switch from a body-worn, external sound processor to a behind-the-ear model
  • Non-FDA-approved devices

This policy is effective March 1, 2017.

77058, 77059

Basic benefit and medical policy

MRI for detection and diagnosis of breast cancer

The safety and effectiveness of MRI of the breast have been established. It may be considered a useful diagnostic option for patients meeting defined criteria.

Inclusionary criteria have been updated, effective March 1, 2017.

Inclusions:

Note: All of the following policy statements refer to performing MRI of the breast with a breast coil and the use of contrast. MRI of the breast without the use of a breast coil, regardless of the clinical indication, is considered experimental.

  1. MRI of the breast may be considered medically appropriate for screening for breast cancer in patients at high risk of breast cancer.

High-risk considerations
There is no standardized method for determining a woman’s risk of breast cancer that incorporates all possible risk factors. There are validated risk prediction models, but they are based primarily on family history.

Some known individual risk factors confer a high risk by themselves. The following list includes factors known to indicate a high risk of breast cancer:

  • Lobular carcinoma in situ
  • A known BRCA1 or BRCA2 mutation or
  • Another gene mutation associated with high risk, e.g., TP53 (Li-Fraumeni syndrome), PTEN (Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome), CDH1 and STK11, ATM, CHEK2 and PALB2
  • High risk (lifetime risk about 20 percent or greater) of developing breast cancer as identified by models that are largely defined by family history 
  • Received radiotherapy to the chest between 10 and 30 years of age

Source: National Cancer Care Network,nccn.org.**

A number of other factors may increase the risk of breast cancer but don’t by themselves indicate high risk. It’s possible that combinations of these factors may be indicative of high risk, but it’s not possible to give quantitative estimates of risk. As a result, it may be necessary to individualize the estimate of risk taking into account numerous risk factors. A number of risk factors, not individually indicating high risk, are included in the National Cancer Institute Breast Cancer Risk Assessment Tool, also called the Gail Model. Risk factors in the model can be accessed at the National Cancer Institute website**.

National Cancer Care Network guidelines state there is insufficient evidence for any recommendations for breast MRI for patients with the following mutations:

  • BARD1
  • FANCC
  • MRE11A
  • MUTYH
  • NF1
  • NBN
  • RAD50
  • SMARCA
  • XRCC2

Moreover, there are conflicting data regarding risks associated with MLH1, MSH2, MSH6, PMS2 and EPCAM gene deletion.
For NCCN guidelines, see Page 24 of the medical policy.

  1. Medically appropriate for the following indications:
    • Detection of a suspected occult breast primary tumor in patients with axillary nodal adenocarcinoma (i.e., negative mammography and physical exam)
    • Presurgical planning in patients with locally advanced breast cancer before and after completion of neoadjuvant chemotherapy to permit tumor localization and characterization
    • Determining the presence of pectoralis major muscle or chest wall invasion in patients with posteriorly located tumor
    • Evaluation of the contralateral breast in those patients with a new diagnosis of breast cancer when clinical and mammographic findings are normal
    • Preoperative tumor mapping of the involved (ipsilateral) breast to evaluate the presence of multicentric disease in patients with clinically localized breast cancer who are candidates for breast-conservation therapy
    • Evaluation of a documented abnormality of the breast before obtaining an MRI-guided biopsy when there is documentation that other methods, such as palpation or ultrasound, aren’t able to localize the lesion for biopsy

Exclusions:

  • Screening technique in average-risk patients
  • Screening technique for the detection of breast cancer when the sensitivity of mammography is limited (i.e., dense breasts, breast implants, scarring after treatment for breast cancer)
  • Diagnosis of low-suspicion findings on conventional testing not indicated for immediate biopsy and referred for short-interval follow-up
  • Diagnosis of a suspicious breast lesion in order to avoid biopsy
  • Determination of a response during neoadjuvant chemotherapy in patients with locally advanced breast cancer, when surgery isn’t planned
  • Evaluation of residual tumor in patients with positive margins after lumpectomy

** Blue Cross Blue Shield of Michigan does not control this website or endorse its general content.

Established: 76499

Experimental: S8080

Basic benefit and medical policy

Scintimammography and gamma imaging of breast and axilla

Scintimammography, breast-specific gamma imaging, or BSGI, and molecular breast imaging, or MBI, are considered experimental for all applications including, but not limited to, their use as adjuncts to mammography or in staging the axillary lymph nodes.  They have not been scientifically demonstrated to improve patient clinical outcomes.

The safety and effectiveness of localization of sentinel lymph nodes using radiopharmaceutical and gamma detection has been established. It may be considered a useful therapeutic or diagnostic option when indicated.

This policy is effective March 1, 2017.

Established: 81228, 81229, 81405, 88271, 88272, 88274, 88275, 59000, 59012

Experimental: 81479

Basic benefit and medical policy

Invasive prenatal (fetal) diagnostic testing

The following criteria have been established. This policy is effective March 1, 2017.

Chromosomal microarray
In patients who are undergoing invasive diagnostic prenatal (fetal) testing, chromosome microarray analysis testing may be considered established, as an alternative to karyotyping.

Single-gene disorders
Invasive diagnostic prenatal (fetal) testing for molecular analysis for single-gene disorders may be considered established when a pregnancy has been identified as being at high risk:

  • For autosomal dominant conditions, at least one of the parents has a known pathogenic mutation.
  • For one of the autosomal recessive conditions:
    • Both parents are suspected to be carriers or are known to be carriers.
    • One parent is clinically affected and the other parent is suspected to be or is a known carrier.
  • For X-linked conditions: a parent is suspected to be or is a known carrier.

And all of the following are met:

  • The natural history of the disease is well understood, and there is a reasonable likelihood that the disease is one with high morbidity in the homozygous or compound heterozygous state.
  • The disease has high penetrance.
  • The genetic test has adequate sensitivity and specificity to guide clinical decision-making and residual risk is understood.
  • An association of the marker with the disorder has been established.

If the above criteria for molecular analysis for single-gene disorders aren’t met, invasive diagnostic prenatal (fetal) testing is considered experimental.

Next-generation sequencing
The use of next-generation sequencing in the setting of invasive prenatal testing is considered experimental.

J3490, J3590, J1599

Basic benefit and medical policy

Stelara IV and Cuvitru

Stelara IV and Cuvitru are included in the Specialty Pharmacy Prior-Authorization Program, effective Nov. 1, 2016.

POLICY CLARIFICATIONS

Payable Procedures
L6715, L6880, L6026, L6881, L6882,
L6920, L6925, L6930, L6935, L6940,
L6945, L6950, L6955, L6965, L6975,
L7007, L7008, L7009, L7045, L7170, L7180, L7181, L7185, L7186, L7190,
L7191, L7259

Basic benefit and medical policy

Myoelectric prosthetic components for the upper limb

The safety and effectiveness of myoelectronic prostheses have been established. They may be considered useful therapeutic options for carefully selected candidates.

The safety and effectiveness of myoelectronic prosthesis with whole hand individually powered digits have been established. They may be considered useful therapeutic options for carefully selected candidates.

A partial hand prosthesis with individually powered digits is considered investigational. This policy was effective Nov. 1, 2016.

Note:  Procedure code L6715 is applicable as a “replacement” for a bad digit on an existing L6880 hand and not a covered benefit when applied as an “initial issue” or for amputations below the wrist.

Inclusions
Myoelectric upper-limb prosthetic components may be considered established when all of the following conditions are met:

  • The patient has an amputation or missing limb at the wrist or above (forearm, elbow, etc.).
  • Standard body-powered prosthetic devices can’t be used or are insufficient to meet the functional needs of the individual in performing activities of daily living.
  • The remaining musculature of the arm or arms contains the minimum microvolt threshold to allow operation of a myoelectric prosthetic device
  • The patient has demonstrated sufficient neurologic and cognitive function to operate the prosthesis effectively.
  • The patient is free of comorbidities that could interfere with function of the prosthesis (neuromuscular disease, etc.).
  • Functional evaluation indicates that with training, use of a myoelectric prosthesis is likely to meet the functional needs of the individual (e.g., gripping, releasing, holding, coordinating movement of the prosthesis) when performing activities of daily living. This evaluation should consider the patient’s needs for control, durability (maintenance), function (speed, work capability) and usability.

Children age 2 and older who have shown at least six months successful use of a passive prosthetic device and have a minimum EMG signal of 6μV threshold.

Myoelectric upper-limb whole prosthetic hands with independent articulating digits (L6880) may be considered established when all of the following conditions are met:

  • Must meet the above criteria for a myoelectric upper limb prosthetic
  • The patient has an amputation or missing limb at the wrist or above (forearm, elbow, etc.).
  • A standard myoelectric prosthesis has been used for one year or more and found insufficient to meet the functional needs of the individual in performing activities of daily living.

Exclusions

  • A partial hand prosthesis with independent articulating digits
  • Whose ADLs require frequent lifting of heavy objects (12 pounds or greater)
  • Whose environments involve frequent contact with dirt, dust, grease, water and solvent
  • Whose neuromas or phantom limb pain are exacerbated with the use of the prosthesis

Myoelectric upper-limb prosthetic components are considered not medically necessary under all other conditions.

EXPERIMENTAL PROCEDURES

0310T

Basic benefit and medical policy

Navigated transcranial magnetic stimulation, or nTMS

The medical policy has been updated for the navigated transcranial magnetic stimulation, or nTMS. This policy is effective March 1, 2017.

Navigated transcranial magnetic stimulation is considered experimental for all purposes including, but not limited to, the preoperative evaluation of patients being considered for brain surgery, when localization of eloquent areas of the brain (e.g., controlling verbal or motor function) is an important consideration in surgical planning.

77061, 77062, 77063, G0279

Basic benefit and medical policy

Digital breast tomosynthesis

This policy remains investigational. The clinical utility of digital tomosynthesis (3-D mammography) in the screening and diagnosis of breast cancer has not been demonstrated. In addition, there is insufficient evidence that the use of digital tomosynthesis (3-D mammography) improves health outcomes, therefore it’s considered experimental.

This policy is effective March 1, 2017.

90750

Basic benefit and medical policy

Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted

The U.S. FDA has not approved the Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular injection; therefore, this vaccine is experimental, effective Jan. 1, 2017.

GROUP BENEFIT CHANGES

Grede Holdings LLC

Grede Holdings LLC, group number 71743, joined Blue Cross Blue Shield of Michigan, effective Jan. 1, 2017.

Group 71743
Alpha Prefix – PPO (NUO)
Platform – NASCO

Plans offered:
PPO
Medical/surgical
Prescription drugs relates only to Brillion Retirees (Wisconsin)

Syncreon RBB

Effective Jan. 1, 2017, Syncreon RBB is offering its members a reference-based benefit product add-on. For more information on RBB, see December’s Record article about Syncreon and RBB.

Group number: 71316
Suffixes: 220 and 221
Alpha prefix: TDU


Professionals

Professional providers will soon be required to submit claims electronically

In 2009, Blue Cross Blue Shield of Michigan began looking for ways to transition some of the 5 million paper claims received annually to electronic claims. We’ve made tremendous strides since then, reducing the number of paper claims by nearly 80 percent to the 1.1 million paper claims we receive today. We’re committed to working closely with health care providers to continue to reduce the number of costly, inefficient paper claims and resubmissions.

Starting June 30, 2017, participating providers will be required to submit the following types of claims electronically:

  • Original claims
  • Replacement claims
  • Void or cancel claims
  • Any claim that includes services for which you will submit medical records

Claims excluded from the electronic submission requirement are:

  • Coordination of benefits tertiary claims
  • COB secondary claims
  • Claims for specified human organ and bone marrow transplants
  • Medicaid claims
  • Medicare Advantage claims
  • Blue Care Network claims

Have questions?

  • If you have any electronic claims questions, contact the Electronic Data Interchange help desk at 1-800-542-0945.
  • For assistance with reporting this information using your practice management system, contact your software vendor or clearinghouse.
  • If you need information on the status of a claim you submitted or have any other questions, contact Provider Inquiry.
  • If you have additional concerns that can’t be addressed by Provider Inquiry, contact your provider consultant.

Here’s what you need to know about providing up-to- date demographic data

At Blue Cross Blue Shield of Michigan, we’re continually working to improve the quality of information in our provider directories.

Members need to know how to get in contact with physicians who participate with their insurance plan and where practices are located. All insurance plans are tasked with providing accurate, up-to-date physician information to members.

In fact, last year, the Centers for Medicare & Medicaid Services mandated that Medicare Advantage health plans provide complete and accurate information regarding physicians to members. If a plan fails to provide accurate provider directories, it’s subject to compliance or enforcement actions, including civil monetary penalties and Medicare star ratings or enrollment sanctions.

Here are answers to some frequently asked questions:

What are Blue Cross and Blue Care Network doing to make it easier for providers to attest to their demographic data?
Currently, we’re using Atlas System’s PRIME-Hub online tool to collect practitioner attestations. However, we’ll be transitioning to DirectAssure™, a CAQH Solution® in mid-2017. DirectAssure will work in concert with CAQH’s ProView® program to improve provider directory data. Our goal is to help you avoid frequent outreach for the same information by multiple health care plans, which could create a significant burden on your staff’s time and resources.

Through DirectAssure®, Blue Cross and BCN providers can confirm their directory information in one place, where it can be shared with participating health plans and will meet our quarterly directory attestation requirement. We’ll incorporate the DirectAssure® information into our provider files to give our members the most up-to-date, accurate information.

What do Blue Cross and BCN providers need to do this year?

For the first half of 2017 (until we transition to DirectAssure), all providers will need to attest to their current demographic data through Atlas System’s PRIME-Hub tool. For details, see the June 2016 Record article.

What do I do if my demographic information is incorrect in PRIME-Hub?
To update your demographic information, go to the Enrollment and Changes section of bcbsm.com/providers.

How should I prepare for the move to CAQH’s DirectAssure?
We strongly recommend you continue to update your directory information in CAQH ProView (see July 2016 Record article) to help ensure a smooth transition when we adopt DirectAssure mid-year.

What happens if I fail to comply?
Consistent attestation noncompliance by individual physicians will result in such actions by Blue Cross Blue Shield of Michigan as suppression from our provider directories and suppression of value-based reimbursement for physicians who participate in the Physician Group Incentive Program. If non-compliance continues, you could be terminated from Blue Cross and BCN networks.

For PGIP participants only:

Is there any additional information that providers who participate in the Physician Group Incentive Program need to know about?
Yes. To help ensure compliance, Value Partnerships recently launched an incentive opportunity known as the Provider Directory Data Quality Compliance Program. PGIP physician organizations can elect to submit physician demographic data electronically, thereby bringing their affiliated physicians into compliance. An electronic submission from the physician organization would serve as the attestation on behalf of the practitioner.

For the first half of 2017, PGIP participants will want to confirm with their PO whether it is participating in the Provider Directory Data Quality Compliance Program and will be submitting physician demographic data electronically on your behalf. If your PO isn’t participating in the electronic file submission, you must attest to your current demographic data by using the PRIME-Hub online tool and then DirectAssure later in the year.

For more information, PGIP participating physicians can contact their PO. Non-PGIP physicians, contact your provider consultant.


Provider forums coming to a town near you

Blue Cross Blue Shield of Michigan and Blue Care Network provider forums are coming to you. While we don’t have all the details yet, we’re announcing the dates and locations so you can save the date. Look for registration information and details on the covered topics in a future issue of The Record.

We look forward to seeing you.

Forum location

Date

Time

Forum focus

Port Huron
DoubleTree by Hilton
800 Harker St.
Port Huron, MI 48060

Wednesday, May 10

8 a.m. to 4 p.m.

Professional providers

Ann Arbor
Courtyard Marriott
3205 Boardwalk Drive
Ann Arbor, MI 48108

Monday, May 15

8 a.m. to 4 p.m.

Professional providers

Novi
Crowne Plaza
27000 Karevich Drive
Novi, MI 48377

Wednesday, May 17

8 a.m. to 4 p.m.

Professional providers

Pontiac/Auburn Hills
Hilton Suites
2300 Featherstone Road
Auburn Hills, MI 48326

Thursday, May 18

8 a.m. to 4 p.m.

Professional providers

Grand Rapids
DoubleTree by Hilton
4747 28th St. SE
Grand Rapids, MI 49512

Tuesday, May 23

8 a.m. to 4 p.m.

Professional providers

Kalamazoo
Four Points by Sheraton
3600 E. Cork Street Court Kalamazoo, MI 49001

Wednesday, May 24

8 a.m. to 4 p.m.

Professional providers

Frankenmuth
Bavarian Inn Lodge
1 Covered Bridge Lane Frankenmuth, MI 48734

Tuesday, June 6

8 a.m. to 4 p.m.

Professional providers

Sterling Heights
Wyndham Garden
34911 Van Dyke
Sterling Heights, MI 48312

Thursday, June 8

8 a.m. to 4 p.m.

Professional providers

Traverse City
West Bay Beach
615 E Front St.
Traverse City, MI 49686

Tuesday, June 13

8 a.m. to 4 p.m.

Professional providers

Okemos
Holiday Inn Express & Suites
2209 University Park Drive Okemos, MI 48864

Tuesday, June 20

8 a.m. to 4 p.m.

Professional providers

Marquette
Holiday Inn
1951 US-41
Marquette, MI 49855

Tuesday, June 27

9 a.m. to 5 p.m.

Professional providers

Marquette
Holiday Inn
1951 US-41
Marquette, MI 49855

Wednesday, June 28

9 a.m. to 5 p.m.

Facility providers


Here’s what you need to know about Blue Distinction Total Care

In previous articles and other communications, we’ve told you about Blue Distinction Total Care, a Blue Cross and Blue Shield Association program. We’d like to provide a brief refresher, highlighting what you need to know.

  • Blue Distinction Total Care is a national program that connects members of out-of-state Blue plans with health care providers in our Patient-Centered Medical Home and Organized Systems of Care programs. Also, Blue Cross Blue Shield of Michigan members who reside outside of Michigan are connected to high-quality health care providers in other states.
  • Michigan physicians who have PCMH designation or who participate in our OSC program are considered Blue Distinction Total Care providers.
  • We help steer members to BDTC doctors through our Find a Doctor search tool on bcbsm.com.

What do Patient-Centered Medical Homes and Organized Systems of Care need to know?

Patient-Centered Medical Homes

Organized Systems of Care

Only PCMH-designated physicians are reimbursed for care coordination services for eligible patients through the existing provider-delivered care management program.

Practices that are part of an Organized System of Care — even if they aren’t designated as Patient-Centered Medical Homes — are considered Blue Distinction Total Care providers.

PCMH-designated physicians will receive patient lists that include attributed host plan members who are BDTC-eligible. In the near future, PCMH-designated physicians will also receive clinical data for members of an out-of-state Blue plan, enabling them to better track their care.

OSC specialists and OSC primary care physicians who aren’t patient-centered medical home designated are not eligible to bill for provider-delivered care management services.

How does Blue Distinction Total Care work for different provider types?

 

PCMH-designated primary care doctors

Non-PCMH-designated primary care doctors in OSCs

Specialists in OSCs

Will be identified as BDTC provider in “Find a Doctor”?

Yes

Yes

Yes

Can bill PDCM codes for attributed members?

Yes

No

No**

Will receive patient lists that include attributed host plan members who are BDTC-eligible?

Yes. These lists are the same as your monthly patient lists, only they now include hosted members.

No

No

Will receive clinical data for members of an out-of-state Blue Cross plan, enabling them to better track their care?

This data is being developed this year to be included in patient lists.

No

No

**Note: Some specialty types will be eligible to bill for PDCM services as part of the PDCM specialty program, starting July 1, 2017. Send an email to valuepartnerships@bcbsm.com for more information.

Future Blue Cross plans include products that will steer members to BDTC providers through new products for national PPO customer groups. We expect these products to be available in 2018 and 2019.

For more information
For more information, physicians can contact their physician organization administrators. If you have a specific question and don’t have access to the Physician Group Incentive Program Collaboration site, email your questions to valuepartnerships@bcbsm.com.


New place-of-service code for telemedicine

Starting Jan. 1, 2017, Blue Cross Blue Shield of Michigan adopted the Center for Medicare & Medicaid Services' new place-of-service code, 02-Telehealth.

The POS code indicates the location where services were rendered through telecommunication technology. Always report POS code 02 with the GT modifier. This new billing requirement applies to all telemedicine claims submitted on or after Jan. 1, 2017, regardless of the date of service.

As a reminder, you should report online visit procedure codes (*98969 and *99444) and telephone evaluation and management visits (*98966, *98967, *98968, *99441, *99442 and *99443) in an office location (11). The new place of service code 02 doesn’t apply to online visits and telephone evaluation and management visits. Also, these eight codes don't require the GT modifier.

These billing guidelines are consistent with the National Correct Coding Initiative and Blue Cross payment policy guidelines and are subject to audit review.

Are you using Clear Claim Connection?

If you’re using Clear Claim Connection, you’ll need to follow a somewhat different process until we’re able to update the Clear Claim Connection tool to accommodate the new place-of-service code. For telehealth place of service (02), select office location (11).


Orthopedic footwear, therapeutic shoes will have quantity, frequency limitations, starting April 2017

Beginning with dates of service on or after April 1, 2017, therapeutic shoes and orthopedic footwear will have quantity and frequency limitations.

Keep the following in mind:

  • A-HCPCS and L-HCPCS codes below require LT or RT modifiers or both.
  • The KX modifier is required for the A-HCPCS codes below ("Therapeutic shoes for persons with diabetes").
  • Claims will reject if you don’t bill the modifiers.
  • If the member requires a shoe or insert because of a diabetes-related condition, submit your claim using the appropriate A-HCPCS code for therapeutic shoes for persons with diabetes.

Therapeutic shoes for persons with diabetes

Procedure code

Quantity and frequency

A5500

2 per year

A5501

2 per year

A5503

2 per year

A5504

2 per year

A5505

2 per year

A5506

2 per year

A5512

6 per year

A5513

6 per year

 

Orthopedic footwear

Procedure code

Quantity and frequency

 

Procedure code

Quantity and frequency

 

Procedure code

Quantity and frequency

L3000

2 per
3 years

L3215

2 per year

L3410

2 per
6 months

L3001

2 per year

L3216

2 per year

L3420

2 per
6 months

L3002

2 per year

L3217

2 per year

L3430

2 per
6 months

L3003

2 per year

L3219

2 per year

L3440

2 per
6 months

L3010

2 per
3 years

L3221

2 per year

L3450

2 per
6 months

L3020

2 per
3 years

L3222

2 per year

L3455

2 per
6 months

L3030

2 per
3 years

L3224

2 per year

L3460

2 per
6 months

L3031

2 per
3 years

L3225

2 per year

L3465

2 per
6 months

L3040

2 per year

L3230

2 per year

L3470

2 per
6 months

L3050

2 per year

L3250

2 per year

L3480

2 per
6 months

L3060

2 per year

L3251

2 per year

L3485

2 per
6 months

L3070

2 per year

L3252

2 per year

L3500

2 per
6 months

L3080

2 per year

L3253

2 per year

L3510

2 per
6 months

L3090

2 per year

L3254

1 per year

L3520

2 per
6 months

L3100

1 per
3 years

L3255

1 per year

L3530

2 per
6 months

L3140

1 per
3 years

L3257

1 per year

L3540

2 per
6 months

L3150

1 per
3 years

L3260

1 per year

L3550

2 per
6 months

L3160

2 per
6 months

L3265

1 per year

L3560

2 per
6 months

L3170

2 per
6 months

L3300

3 per
6 months

L3570

2 per
6 months

L3201

2 per
6 months

L3310

3 per
6 months

L3580

2 per
6 months

L3202

2 per
6 months

L3320

3 per
6 months

L3590

2 per
6 months

L3203

2 per
6 months

L3330

2 per
6 months

L3595

2 per
6 months

L3204

2 per
6 months

L3332

2 per
6 months

L3600

2 per
6 months

L3206

2 per
6 months

L3334

3 per
6 months

L3610

2 per
6 months

L3207

2 per
6 months

L3340

2 per
6 months

L3620

2 per
6 months

L3208

2 per
6 months

L3350

2 per
6 months

L3630

2 per
6 months

L3209

2 per
6 months

L3360

2 per
6 months

L3640

2 per
6 months

L3211

2 per
6 months

L3370

2 per
6 months

L3440

2 per
6 months

L3212

2 per
6 months

L3380

2 per
6 months

L3450

2 per
6 months

L3213

2 per
6 months

L3390

2 per
6 months

L3455

2 per
6 months

L3214

2 per
6 months

L3400

2 per
6 months

 


Reminder: Supporting documentation required for billing procedure codes reported with modifier 62

“Co-surgery” refers to a single surgical procedure that requires the skill of two surgeons. The two surgeons, who are from the same specialty or different ones, perform parts of the same procedure.

Procedure codes reported with “modifier 62 – co-surgery” must be submitted with the operative report. If no additional documentation is submitted, the service will be rejected, with a message indicating that supporting documentation is required before payment can be considered.

Note: Co-surgeons should coordinate their claim submissions within the same time frame, and both providers should use modifier 62. If the claims aren’t coordinated or modifier 62 isn’t used, the second surgeon’s claim may be rejected.

For additional information about reporting services that always require medical records, refer to the Claims chapter of the online provider manual.


Payable diagnosis codes for procedure codes *98940, *98941 and *98942 have changed

Blue Cross Blue Shield of Michigan is aligning its policy for spinal manipulation with Medicare’s payable diagnostic codes. We’re adding all diagnostic codes payable by Medicare. This will affect procedure codes *98940, *98941 and *98942. Click here to see the list of affected codes.


Payable diagnosis codes for procedure codes J0882, J0887 and Q4081 have changed

Blue Cross Blue Shield of Michigan is aligning its policy for procedure codes J0882, J0887 and Q4081 with Medicare’s payable diagnostic codes. We’re adding all diagnostic codes payable by Medicare. Click here to see the list of affected codes.


Facility

Provider forums coming to a town near you

Blue Cross Blue Shield of Michigan and Blue Care Network provider forums are coming to you. While we don’t have all the details yet, we’re announcing the dates and locations so you can save the date. Look for registration information and details on the covered topics in a future issue of The Record.

We look forward to seeing you.

Forum location

Date

Time

Forum focus

Port Huron
DoubleTree by Hilton
800 Harker St.
Port Huron, MI 48060

Wednesday, May 10

8 a.m. to 4 p.m.

Professional providers

Ann Arbor
Courtyard Marriott
3205 Boardwalk Drive
Ann Arbor, MI 48108

Monday, May 15

8 a.m. to 4 p.m.

Professional providers

Novi
Crowne Plaza
27000 Karevich Drive
Novi, MI 48377

Wednesday, May 17

8 a.m. to 4 p.m.

Professional providers

Pontiac/Auburn Hills
Hilton Suites
2300 Featherstone Road
Auburn Hills, MI 48326

Thursday, May 18

8 a.m. to 4 p.m.

Professional providers

Grand Rapids
DoubleTree by Hilton
4747 28th St. SE
Grand Rapids, MI 49512

Tuesday, May 23

8 a.m. to 4 p.m.

Professional providers

Kalamazoo
Four Points by Sheraton
3600 E. Cork Street Court Kalamazoo, MI 49001

Wednesday, May 24

8 a.m. to 4 p.m.

Professional providers

Frankenmuth
Bavarian Inn Lodge
1 Covered Bridge Lane Frankenmuth, MI 48734

Tuesday, June 6

8 a.m. to 4 p.m.

Professional providers

Sterling Heights
Wyndham Garden
34911 Van Dyke
Sterling Heights, MI 48312

Thursday, June 8

8 a.m. to 4 p.m.

Professional providers

Traverse City
West Bay Beach
615 E Front St.
Traverse City, MI 49686

Tuesday, June 13

8 a.m. to 4 p.m.

Professional providers

Okemos
Holiday Inn Express & Suites
2209 University Park Drive Okemos, MI 48864

Tuesday, June 20

8 a.m. to 4 p.m.

Professional providers

Marquette
Holiday Inn
1951 US-41
Marquette, MI 49855

Tuesday, June 27

9 a.m. to 5 p.m.

Professional providers

Marquette
Holiday Inn
1951 US-41
Marquette, MI 49855

Wednesday, June 28

9 a.m. to 5 p.m.

Facility providers


Reminder: Supporting documentation required for billing procedure codes reported with modifier 62

“Co-surgery” refers to a single surgical procedure that requires the skill of two surgeons. The two surgeons, who are from the same specialty or different ones, perform parts of the same procedure.

Procedure codes reported with “modifier 62 – co-surgery” must be submitted with the operative report. If no additional documentation is submitted, the service will be rejected, with a message indicating that supporting documentation is required before payment can be considered.

Note: Co-surgeons should coordinate their claim submissions within the same time frame, and both providers should use modifier 62. If the claims aren’t coordinated or modifier 62 isn’t used, the second surgeon’s claim may be rejected.

For additional information about reporting services that always require medical records, refer to the Claims chapter of the online provider manual.


All hospitals must give Medicare Outpatient Observation Notice to patient

Blue Cross Blue Shield of Michigan adheres to guidance from the Centers for Medicare & Medicaid Services for the Medicare Outpatient Observation Notice, commonly referred to as MOON.

Effective Feb. 21, 2017, hospitals and critical access hospitals are required to furnish the MOON to any Medicare beneficiary who has been receiving observation services as an outpatient for more than 24 hours. This is a mandatory requirement for all hospitals.

The MOON is a standardized notice that informs beneficiaries (including Medicare health plan enrollees) that they are an outpatient receiving observation services and are not an inpatient of the hospital or a critical access hospital. The notice must be provided no later than 36 hours after observation services are initiated or, if sooner, upon release.

The notice informs beneficiaries of the reasons they’re an outpatient receiving observation services and how this may affect their Medicare cost sharing and coverage for post-hospitalization skilled nursing facility services.

You can find the standard language for the MOON and instructions on the CMS website by clicking here.**

**Blue Cross doesn’t own or control this website.


DME

Orthopedic footwear, therapeutic shoes will have quantity, frequency limitations, starting April 2017

Beginning with dates of service on or after April 1, 2017, therapeutic shoes and orthopedic footwear will have quantity and frequency limitations.

Keep the following in mind:

  • A-HCPCS and L-HCPCS codes below require LT or RT modifiers or both.
  • The KX modifier is required for the A-HCPCS codes below ("Therapeutic shoes for persons with diabetes").
  • Claims will reject if you don’t bill the modifiers.
  • If the member requires a shoe or insert because of a diabetes-related condition, submit your claim using the appropriate A-HCPCS code for therapeutic shoes for persons with diabetes.

Therapeutic shoes for persons with diabetes

Procedure code

Quantity and frequency

A5500

2 per year

A5501

2 per year

A5503

2 per year

A5504

2 per year

A5505

2 per year

A5506

2 per year

A5512

6 per year

A5513

6 per year

 

Orthopedic footwear

Procedure code

Quantity and frequency

 

Procedure code

Quantity and frequency

 

Procedure code

Quantity and frequency

L3000

2 per
3 years

L3215

2 per year

L3410

2 per
6 months

L3001

2 per year

L3216

2 per year

L3420

2 per
6 months

L3002

2 per year

L3217

2 per year

L3430

2 per
6 months

L3003

2 per year

L3219

2 per year

L3440

2 per
6 months

L3010

2 per
3 years

L3221

2 per year

L3450

2 per
6 months

L3020

2 per
3 years

L3222

2 per year

L3455

2 per
6 months

L3030

2 per
3 years

L3224

2 per year

L3460

2 per
6 months

L3031

2 per
3 years

L3225

2 per year

L3465

2 per
6 months

L3040

2 per year

L3230

2 per year

L3470

2 per
6 months

L3050

2 per year

L3250

2 per year

L3480

2 per
6 months

L3060

2 per year

L3251

2 per year

L3485

2 per
6 months

L3070

2 per year

L3252

2 per year

L3500

2 per
6 months

L3080

2 per year

L3253

2 per year

L3510

2 per
6 months

L3090

2 per year

L3254

1 per year

L3520

2 per
6 months

L3100

1 per
3 years

L3255

1 per year

L3530

2 per
6 months

L3140

1 per
3 years

L3257

1 per year

L3540

2 per
6 months

L3150

1 per
3 years

L3260

1 per year

L3550

2 per
6 months

L3160

2 per
6 months

L3265

1 per year

L3560

2 per
6 months

L3170

2 per
6 months

L3300

3 per
6 months

L3570

2 per
6 months

L3201

2 per
6 months

L3310

3 per
6 months

L3580

2 per
6 months

L3202

2 per
6 months

L3320

3 per
6 months

L3590

2 per
6 months

L3203

2 per
6 months

L3330

2 per
6 months

L3595

2 per
6 months

L3204

2 per
6 months

L3332

2 per
6 months

L3600

2 per
6 months

L3206

2 per
6 months

L3334

3 per
6 months

L3610

2 per
6 months

L3207

2 per
6 months

L3340

2 per
6 months

L3620

2 per
6 months

L3208

2 per
6 months

L3350

2 per
6 months

L3630

2 per
6 months

L3209

2 per
6 months

L3360

2 per
6 months

L3640

2 per
6 months

L3211

2 per
6 months

L3370

2 per
6 months

L3440

2 per
6 months

L3212

2 per
6 months

L3380

2 per
6 months

L3450

2 per
6 months

L3213

2 per
6 months

L3390

2 per
6 months

L3455

2 per
6 months

L3214

2 per
6 months

L3400

2 per
6 months

 


Medicare Advantage

Here’s what you need to know about providing up-to- date demographic data

At Blue Cross Blue Shield of Michigan, we’re continually working to improve the quality of information in our provider directories.

Members need to know how to get in contact with physicians who participate with their insurance plan and where practices are located. All insurance plans are tasked with providing accurate, up-to-date physician information to members.

In fact, last year, the Centers for Medicare & Medicaid Services mandated that Medicare Advantage health plans provide complete and accurate information regarding physicians to members. If a plan fails to provide accurate provider directories, it’s subject to compliance or enforcement actions, including civil monetary penalties and Medicare star ratings or enrollment sanctions.

Here are answers to some frequently asked questions:

What are Blue Cross and Blue Care Network doing to make it easier for providers to attest to their demographic data?
Currently, we’re using Atlas System’s PRIME-Hub online tool to collect practitioner attestations. However, we’ll be transitioning to DirectAssure™, a CAQH Solution® in mid-2017. DirectAssure will work in concert with CAQH’s ProView® program to improve provider directory data. Our goal is to help you avoid frequent outreach for the same information by multiple health care plans, which could create a significant burden on your staff’s time and resources.

Through DirectAssure®, Blue Cross and BCN providers can confirm their directory information in one place, where it can be shared with participating health plans and will meet our quarterly directory attestation requirement. We’ll incorporate the DirectAssure® information into our provider files to give our members the most up-to-date, accurate information.

What do Blue Cross and BCN providers need to do this year?

For the first half of 2017 (until we transition to DirectAssure), all providers will need to attest to their current demographic data through Atlas System’s PRIME-Hub tool. For details, see the June 2016 Record article.

What do I do if my demographic information is incorrect in PRIME-Hub?
To update your demographic information, go to the Enrollment and Changes section of bcbsm.com/providers.

How should I prepare for the move to CAQH’s DirectAssure?
We strongly recommend you continue to update your directory information in CAQH ProView (see July 2016 Record article) to help ensure a smooth transition when we adopt DirectAssure mid-year.

What happens if I fail to comply?
Consistent attestation noncompliance by individual physicians will result in such actions by Blue Cross Blue Shield of Michigan as suppression from our provider directories and suppression of value-based reimbursement for physicians who participate in the Physician Group Incentive Program. If non-compliance continues, you could be terminated from Blue Cross and BCN networks.

For PGIP participants only:

Is there any additional information that providers who participate in the Physician Group Incentive Program need to know about?
Yes. To help ensure compliance, Value Partnerships recently launched an incentive opportunity known as the Provider Directory Data Quality Compliance Program. PGIP physician organizations can elect to submit physician demographic data electronically, thereby bringing their affiliated physicians into compliance. An electronic submission from the physician organization would serve as the attestation on behalf of the practitioner.

For the first half of 2017, PGIP participants will want to confirm with their PO whether it is participating in the Provider Directory Data Quality Compliance Program and will be submitting physician demographic data electronically on your behalf. If your PO isn’t participating in the electronic file submission, you must attest to your current demographic data by using the PRIME-Hub online tool and then DirectAssure later in the year.

For more information, PGIP participating physicians can contact their PO. Non-PGIP physicians, contact your provider consultant.

No portion of this publication may be copied without the express written permission of Blue Cross Blue Shield of Michigan, except that BCBSM participating health care providers may make copies for their personal use. In no event may any portion of this publication be copied or reprinted and used for commercial purposes by any party other than BCBSM.

*CPT codes, descriptions and two-digit numeric modifiers only are copyright 2016 American Medical Association. All rights reserved.